Ozempic (weekly semaglutide) vs Saxenda (daily liraglutide) compared — weight-loss efficacy, dosing convenience, side effects, and cost structure.
Short answer: Both are GLP-1 agonists, but semaglutide (Ozempic/Wegovy) is the more effective molecule: ~15% average weight loss on weekly injection vs ~8% on daily liraglutide (Saxenda) in their respective obesity trials, with a weekly pen instead of daily shots. Saxenda's advantage is longer market history; semaglutide's is efficacy and convenience.
The two molecules
Saxenda is liraglutide 3 mg — a daily GLP-1 injection approved for weight management. Ozempic/Wegovy is semaglutide — a weekly GLP-1 with a longer-acting molecule engineered for greater efficacy.
Head-to-head evidence
The STEP 8 trial directly compared semaglutide 2.4 mg vs liraglutide 3 mg (both with lifestyle support): semaglutide produced roughly −15.8% vs −6.4% mean weight change at 68 weeks — more than double the efficacy in direct comparison.
| Semaglutide (Ozempic/Wegovy) | Liraglutide (Saxenda) |
|---|
| Dosing | Once weekly | Once daily |
| Head-to-head weight loss (STEP 8) | ~15.8% | ~6.4% |
| Separate trial averages | ~15% (STEP 1) | ~8% (SCALE) |
| Class | GLP-1 agonist | GLP-1 agonist |
| Missed-dose impact | Small (weekly schedule) | Larger (daily schedule) |
Side effects
Same class side-effect profile — nausea, vomiting, diarrhea, constipation; gallbladder and pancreatitis warnings apply to both. Semaglutide's greater efficacy comes with comparable GI burden; tolerability is individual.
Practical differences for Nepal
- Weekly vs daily — adherence is meaningfully easier weekly
- Cold chain — both need refrigeration; in-person verified handover matters equally
- Availability — semaglutide has broader global supply chains now; Saxenda's has thinned as semaglutide dominates
- Cost structure — both are ongoing monthly costs; efficacy per rupee favors semaglutide in most comparisons
Yes, but semaglutide has largely superseded it for weight management due to greater efficacy and weekly dosing. It's a reasonable alternative when semaglutide isn't available or tolerated.
Molecular engineering — albumin binding extends its half-life to ~7 days and increases receptor potency vs liraglutide's ~13-hour half-life.
STEP 8 head-to-head trial (JAMA 2022); SCALE trials (liraglutide); FDA labels for Saxenda and Wegovy.